keyword
MENU ▼
Read by QxMD icon Read
search

Price transparency

keyword
https://www.readbyqxmd.com/read/28578735/developments-in-value-frameworks-to-inform-the-allocation-of-healthcare-resources
#1
Wija Oortwijn, Laura Sampietro-Colom, Fay Habens
BACKGROUND: In recent years, there has been a surge in the development of frameworks to assess the value of different types of health technologies to inform healthcare resource allocation. The reasons for, and the potential of, these value frameworks were discussed during the 2017 Health Technology Assessment International (HTAi) Policy Forum Meeting. METHODS: This study reflects the discussion, drawing on presentations from invited experts and Policy Forum members, as well as a background paper...
June 5, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28572733/the-jordan-food-and-drug-administration-comparison-of-its-registration-process-with-australia-canada-saudi-arabia-and-singapore
#2
Wesal Salem Al Haqaish, Hayel Obeidat, Prisha Patel, Stuart Walker
OBJECTIVE: This study outlines the current regulatory review process and good review practices (GRevPs) at the Jordan Food and Drug Administration (JFDA) and compares them with those of regulatory agencies in Australia, Canada, Saudi Arabia and Singapore to gauge how well the JFDA is performing. We identify opportunities for further development of the JFDA as a key global reference agency. METHODS: Personnel within the JFDA completed a questionnaire comprising four sections: organisation, key milestones, review timelines, and GRevPs...
2017: Pharmaceutical Medicine
https://www.readbyqxmd.com/read/28554214/battling-the-chargemaster-a-simple-remedy-to-balance-billing-for-unavoidable-out-of-network-care
#3
Barak D Richman, Nick Kitzman, Arnold Milstein, Kevin A Schulman
OBJECTIVES: To develop an effective legal mechanism to combat chargemaster abuses and to facilitate price transparency. STUDY DESIGN: Applying legal doctrines to out-of-network (OON) billing disputes. METHODS: We reviewed rudimentary contract law and examined the law's handling of contracts where prices have not been specified in advance. These cases are the controlling authority to guide courts, handling of surprise and OON billing problems...
April 1, 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28545614/-hera-quest-hta-evaluation-of-generic-pharmaceutical-products-to-improve-quality-economic-efficiency-patient-safety-and-transparency-in-drug-product-changes-in-hospitals
#4
Miriam Gyalrong-Steur, Anita Kellermann, Rudolf Bernard, Georg Berndt, Meike Bindemann, Elfriede Nusser-Rothermundt, Steffen Amann, Myga Brakebusch, Jörg Brüggmann, Eva Tydecks, Markus Müller, Frank Dörje, Eberhard Kochs, Rainer Riedel
In view of the rising cost pressure and an increasing number of drug shortages, switches between generic drug preparations have become a daily routine in hospitals. To ensure consistently high treatment quality and best possible patient safety, the equivalence of the new and the previous drug preparation must be ensured before any change in the purchase of pharmaceutical products takes place. So far, no easily usable, transparent and standardized instrument for this kind of comparison between generic drug products has been available...
April 2017: Zeitschrift Für Evidenz, Fortbildung und Qualität Im Gesundheitswesen
https://www.readbyqxmd.com/read/28523946/who-uses-a-price-transparency-tool-implications-for-increasing-consumer-engagement
#5
Rebecca A Gourevitch, Sunita Desai, Andrew L Hicks, Laura A Hatfield, Michael E Chernew, Ateev Mehrotra
Despite the recent proliferation of price transparency tools, consumer use and awareness of these tools is low. Better strategies to increase the use of price transparency tools are needed. To inform such efforts, we studied who is most likely to use a price transparency tool. We conducted a cross-sectional study of use of the Truven Treatment Cost Calculator among employees at 2 large companies for the 12 months following the introduction of the tool in 2011-2012. We examined frequency of sign-ons and used multivariate logistic regression to identify which demographic and health care factors were associated with greater use of the tool...
January 1, 2017: Inquiry: a Journal of Medical Care Organization, Provision and Financing
https://www.readbyqxmd.com/read/28523128/comparison-of-medicines-management-strategies-in-insurance-schemes-in-middle-income-countries-four-case-studies
#6
Warren A Kaplan, Paul G Ashigbie, Mohamad I Brooks, Veronika J Wirtz
BACKGROUND: Many middle-income countries are scaling up health insurance schemes to provide financial protection and access to affordable medicines to poor and uninsured populations. Although there is a wealth of evidence on how high income countries with mature insurance schemes manage cost-effective use of medicines, there is limited evidence on the strategies used in middle-income countries. This paper compares the medicines management strategies that four insurance schemes in middle-income countries use to improve access and cost-effective use of medicines among beneficiaries...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28492030/managing-the-dose-escalation-of-biologics-in-an-era-of-cost-containment-the-need-for-a-rational-strategy
#7
K T Shahwan, A B Kimball
Although biologic medications have demonstrated great efficacy for the treatment of psoriasis, a subset of patients fails to respond and others lose response later in the course. In treating a patient who has failed to respond to biologic therapy, clinicians must decide between dose escalation, switching biologics, and adding or switching to a non-biologic systemic drug or phototherapy. Although dose escalation is perhaps the simplest strategy and generally well-tolerated, it confers a tremendous cost burden because doubling the dosage is likely to double the wholesale price...
December 2016: International Journal of Women's Dermatology
https://www.readbyqxmd.com/read/28458429/pricing-and-components-analysis-of-some-key-essential-pediatric-medicine-in-odisha-state
#8
Satyajit Samal, Trupti Rekha Swain
OBJECTIVE: Study highlighting prices, i.e., the patients actually pay at ground level is important for interventions such as alternate procurement schemes or to expedite regulatory assessment of essential medicines for children. The present study was undertaken to study pricing and component analysis of few key essential medicines in Odisha state. METHODOLOGY: Six child-specific medicines of different formulations were selected based on use in different disease condition and having widest pricing variation...
January 2017: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/28449884/a-rapidly-changing-global-medicines-environment-how-adaptable-are-funding-decision-making-systems
#9
Christine Leopold, Steven G Morgan, Anita K Wagner
BACKGROUND: With the launch of very highly priced therapies and sudden price increases of generics, pressures on health systems have drastically increased. OBJECTIVES: We aimed to elicit opinions of key decision makers responsible for national assessment and funding decisions on their experiences to adapt to these new realities. METHODS/SETTING: Through interviews with decision makers of pharmaceutical assessment and/or funding agencies, we describe the challenges systems are currently facing, systems' responses and systems' characteristics facilitating or hindering responses to changes and overarching topics for the future...
April 10, 2017: Health Policy
https://www.readbyqxmd.com/read/28441147/can-the-generic-antiretroviral-industry-support-access-to-a-universal-antiretroviral-regimen
#10
Carolyn D Amole, Caroline Middlecote, Vineet R Prabhu, N Kumarasamy
PURPOSE OF REVIEW: The generic antiretroviral (ARV) industry played a critical role in the massive scale-up of HIV treatment in low-income and middle-income countries since 2000. As the global community looks ahead to a universal antiretroviral regimen, this article considers the industry's role in supporting universal access to affordable, simpler, more durable, and tolerable HIV treatment regimens. RECENT FINDINGS: Generic manufacturers made treatment scale-up in low-income and middle-income countries possible through reducing prices, combining molecules from different originator companies to develop optimal fixed-dose combinations, and investing in production capacity to meet escalating demand...
July 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28430829/effect-of-a-price-transparency-intervention-in-the-electronic-health-record-on-clinician-ordering-of-inpatient-laboratory-tests-the-price-randomized-clinical-trial
#11
Mina S Sedrak, Jennifer S Myers, Dylan S Small, Irving Nachamkin, Justin B Ziemba, Dana Murray, Gregory W Kurtzman, Jingsan Zhu, Wenli Wang, Deborah Mincarelli, Daniel Danoski, Brian P Wells, Jeffrey S Berns, Patrick J Brennan, C William Hanson, C Jessica Dine, Mitesh S Patel
Importance: Many health systems are considering increasing price transparency at the time of order entry. However, evidence of its impact on clinician ordering behavior is inconsistent and limited to single-site evaluations of shorter duration. Objective: To test the effect of displaying Medicare allowable fees for inpatient laboratory tests on clinician ordering behavior over 1 year. Design, Setting, and Participants: The Pragmatic Randomized Introduction of Cost data through the electronic health record (PRICE) trial was a randomized clinical trial comparing a 1-year intervention to a 1-year preintervention period, and adjusting for time trends and patient characteristics...
April 21, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28430828/achieving-the-promise-of-price-transparency
#12
Anna D Sinaiko, Alyna T Chien
No abstract text is available yet for this article.
April 21, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28405793/capsule-commentary-on-saloner-et-al-price-transparency-in-primary-care-can-patients-learn-about-costs-when-scheduling-an-appointment
#13
Cameron M Kaplan
No abstract text is available yet for this article.
April 12, 2017: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/28359063/reimbursed-price-of-orphan-drugs-current-strategies-and-potential-improvements
#14
Pierpaolo Mincarone, Carlo Giacomo Leo, Saverio Sabina, Antonio Sarriá-Santamera, Domenica Taruscio, Pedro Guillermo Serrano-Aguilar, Panos Kanavos
The pricing and reimbursement policies for pharmaceuticals are relevant to balance timely and equitable access for all patients, financial sustainability, and reward for valuable innovation. The proliferation of high-cost specialty medicines is particularly true in rare diseases (RDs) where the pricing mechanism is characterised by a lack of transparency. This work provides an overall picture of current strategies for the definition of the reimbursed prices of orphan drugs (ODs) and highlights some potential improvements...
2017: Public Health Genomics
https://www.readbyqxmd.com/read/28358722/bgo-as-a-hybrid-scintillator-cherenkov-radiator-for-cost-effective-time-of-flight-pet
#15
S E Brunner, D R Schaart
Due to detector developments in the last decade, the time-of-flight (TOF) method is now commonly used to improve the quality of positron emission tomography (PET) images. Clinical TOF-PET systems based on L(Y)SO:Ce crystals and silicon photomultipliers (SiPMs) with coincidence resolving times (CRT) between 325 ps and 400 ps FWHM have recently been developed. Before the introduction of L(Y)SO:Ce, BGO was used in many PET systems. In addition to a lower price, BGO offers a superior attenuation coefficient and a higher photoelectric fraction than L(Y)SO:Ce...
March 30, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28358029/genome-wide-association-study-identifies-three-novel-loci-in-fuchs-endothelial-corneal-dystrophy
#16
Natalie A Afshari, Robert P Igo, Nathan J Morris, Dwight Stambolian, Shiwani Sharma, V Lakshmi Pulagam, Steven Dunn, John F Stamler, Barbara J Truitt, Jacqueline Rimmler, Abraham Kuot, Christopher R Croasdale, Xuejun Qin, Kathryn P Burdon, S Amer Riazuddin, Richard Mills, Sonja Klebe, Mollie A Minear, Jiagang Zhao, Elmer Balajonda, George O Rosenwasser, Keith H Baratz, V Vinod Mootha, Sanjay V Patel, Simon G Gregory, Joan E Bailey-Wilson, Marianne O Price, Francis W Price, Jamie E Craig, John H Fingert, John D Gottsch, Anthony J Aldave, Gordon K Klintworth, Jonathan H Lass, Yi-Ju Li, Sudha K Iyengar
The structure of the cornea is vital to its transparency, and dystrophies that disrupt corneal organization are highly heritable. To understand the genetic aetiology of Fuchs endothelial corneal dystrophy (FECD), the most prevalent corneal disorder requiring transplantation, we conducted a genome-wide association study (GWAS) on 1,404 FECD cases and 2,564 controls of European ancestry, followed by replication and meta-analysis, for a total of 2,075 cases and 3,342 controls. We identify three novel loci meeting genome-wide significance (P<5 × 10(-8)): KANK4 rs79742895, LAMC1 rs3768617 and LINC00970/ATP1B1 rs1200114...
March 30, 2017: Nature Communications
https://www.readbyqxmd.com/read/28345445/the-role-of-patient-financial-assistance-programs-in-reducing-costs-for-cancer-patients
#17
Leah L Zullig, Steven Wolf, Lisa Vlastelica, Veena Shankaran, S Yousuf Zafar
BACKGROUND: Limited transparency exists regarding eligibility and benefits for patient financial assistance programs (PAPs). OBJECTIVE: To describe oral anticancer medication costs, insurance coverage, and the degree of financial assistance provided by PAPs. METHODS: This was a retrospective study of prescription anticancer medication costs and PAP coverage. The study used data from an academic cancer center's specialty pharmacy. Medication, cost, and coverage data were collected from the specialty pharmacy database for prescriptions filled from January 2013 to November 2015...
April 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28321145/drug-pricing-transparency-the-new-retail-revolution
#18
Kaitlyn N Dana, John B Hertig, Robert J Weber
As spending on medications in the United States increases with each passing year, the need for drug pricing transparency by manufacturers also increases. Drug spending, excluding rebates and discounts, was $309.5 billion in 2015, up 8.5% from 2014. Drug pricing transparency has been a topic of debate across the health care system. This column reviews the issue of drug pricing and emphasizes the need for transparency in this area. We will discuss factors that influence drug pricing, policies and ways to reduce the rising costs of drugs, and the role of pharmacy leaders in managing this problem...
February 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/28303438/using-health-technology-assessment-to-assess-the-value-of-new-medicines-results-of-a-systematic-review-and-expert-consultation-across-eight-european-countries
#19
Aris Angelis, Ansgar Lange, Panos Kanavos
BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value. OBJECTIVE: To study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment...
March 16, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28282117/metal-selenides-as-efficient-counter-electrodes-for-dye-sensitized-solar-cells
#20
Zhitong Jin, Meirong Zhang, Min Wang, Chuanqi Feng, Zhong-Sheng Wang
Solar energy is the most abundant renewable energy available to the earth and can meet the energy needs of humankind, but efficient conversion of solar energy to electricity is an urgent issue of scientific research. As the third-generation photovoltaic technology, dye-sensitized solar cells (DSSCs) have gained great attention since the landmark efficiency of ∼7% reported by O'Regan and Grätzel. The most attractive features of DSSCs include low cost, simple manufacturing processes, medium-purity materials, and theoretically high power conversion efficiencies...
March 10, 2017: Accounts of Chemical Research
keyword
keyword
80684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"